The global Ifosfamide for Injection market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Ifosfamide for injection (IFO) is an isomer of cyclophosphamide. When it enters the body, it is hydrolyzed by phosphatase or phosphatase in the liver or tumor, and becomes activated phosphoramide nitrogen mustard to work. Its mechanism of action is to cross-link with DNA, inhibit DNA synthesis, and also interfere with RNA function. It is a non-specific drug for the cell cycle. This product has a wide anti-tumor spectrum and has inhibitory effects on many tumors.

From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Ifosfamide for Injection leading manufacturers including Hanhui Pharmaceuticals, Harbin Sanlian Pharmaceuticals, Sinopharm Group, Hainan Zhuotai Pharmaceuticals, Nanjing Pharmaceutical Factory, Qilu Pharmaceuticals, Jiangsu Hengrui Medicines, Shanxi Pude Pharmaceuticals, Baxter, Fresenius Kabi Pharmaceuticals, etc., dominate supply; the top five capture approximately % of global revenue, with Hanhui Pharmaceuticals leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Ifosfamide for Injection market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Ifosfamide for Injection Market Report

Report Metric	Details
Report Name	Ifosfamide for Injection Market
Segment by Type	3.0g 1.0g 0.5g
Segment by Application	Hospital Clinic Other
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Hanhui Pharmaceuticals, Harbin Sanlian Pharmaceuticals, Sinopharm Group, Hainan Zhuotai Pharmaceuticals, Nanjing Pharmaceutical Factory, Qilu Pharmaceuticals, Jiangsu Hengrui Medicines, Shanxi Pude Pharmaceuticals, Baxter, Fresenius Kabi Pharmaceuticals, Pfizer, Mylan, Hikma Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Ifosfamide for Injection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Ifosfamide for Injection Market report?

Ans: The main players in the Ifosfamide for Injection Market are Hanhui Pharmaceuticals, Harbin Sanlian Pharmaceuticals, Sinopharm Group, Hainan Zhuotai Pharmaceuticals, Nanjing Pharmaceutical Factory, Qilu Pharmaceuticals, Jiangsu Hengrui Medicines, Shanxi Pude Pharmaceuticals, Baxter, Fresenius Kabi Pharmaceuticals, Pfizer, Mylan, Hikma Pharmaceuticals

What are the Application segmentation covered in the Ifosfamide for Injection Market report?

Ans: The Applications covered in the Ifosfamide for Injection Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Ifosfamide for Injection Market report?

Ans: The Types covered in the Ifosfamide for Injection Market report are 3.0g, 1.0g, 0.5g

1 Study Coverage

1.1 Introduction to Ifosfamide for Injection: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Ifosfamide for Injection Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 3.0g

1.2.3 1.0g

1.2.4 0.5g

1.3 Market Segmentation by Application

1.3.1 Global Ifosfamide for Injection Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Ifosfamide for Injection Revenue Estimates and Forecasts 2020-2031

2.2 Global Ifosfamide for Injection Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Ifosfamide for Injection Sales Estimates and Forecasts 2020-2031

2.4 Global Ifosfamide for Injection Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global Ifosfamide for Injection Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global Ifosfamide for Injection Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 3.0g Market Size by Manufacturers

3.5.2 1.0g Market Size by Manufacturers

3.5.3 0.5g Market Size by Manufacturers

3.6 Global Ifosfamide for Injection Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Ifosfamide for Injection Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global Ifosfamide for Injection Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Ifosfamide for Injection Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global Ifosfamide for Injection Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America Ifosfamide for Injection Sales and Revenue by Type (2020-2031)

6.4 North America Ifosfamide for Injection Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Ifosfamide for Injection Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe Ifosfamide for Injection Sales and Revenue by Type (2020-2031)

7.4 Europe Ifosfamide for Injection Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Ifosfamide for Injection Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific Ifosfamide for Injection Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific Ifosfamide for Injection Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific Ifosfamide for Injection Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America Ifosfamide for Injection Sales and Revenue by Type (2020-2031)

9.4 Central and South America Ifosfamide for Injection Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Ifosfamide for Injection Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa Ifosfamide for Injection Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa Ifosfamide for Injection Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Ifosfamide for Injection Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Hanhui Pharmaceuticals

11.1.1 Hanhui Pharmaceuticals Corporation Information

11.1.2 Hanhui Pharmaceuticals Business Overview

11.1.3 Hanhui Pharmaceuticals Ifosfamide for Injection Product Models, Descriptions and Specifications

11.1.4 Hanhui Pharmaceuticals Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Hanhui Pharmaceuticals Ifosfamide for Injection Sales by Product in 2024

11.1.6 Hanhui Pharmaceuticals Ifosfamide for Injection Sales by Application in 2024

11.1.7 Hanhui Pharmaceuticals Ifosfamide for Injection Sales by Geographic Area in 2024

11.1.8 Hanhui Pharmaceuticals Ifosfamide for Injection SWOT Analysis

11.1.9 Hanhui Pharmaceuticals Recent Developments

11.2 Harbin Sanlian Pharmaceuticals

11.2.1 Harbin Sanlian Pharmaceuticals Corporation Information

11.2.2 Harbin Sanlian Pharmaceuticals Business Overview

11.2.3 Harbin Sanlian Pharmaceuticals Ifosfamide for Injection Product Models, Descriptions and Specifications

11.2.4 Harbin Sanlian Pharmaceuticals Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 Harbin Sanlian Pharmaceuticals Ifosfamide for Injection Sales by Product in 2024

11.2.6 Harbin Sanlian Pharmaceuticals Ifosfamide for Injection Sales by Application in 2024

11.2.7 Harbin Sanlian Pharmaceuticals Ifosfamide for Injection Sales by Geographic Area in 2024

11.2.8 Harbin Sanlian Pharmaceuticals Ifosfamide for Injection SWOT Analysis

11.2.9 Harbin Sanlian Pharmaceuticals Recent Developments

11.3 Sinopharm Group

11.3.1 Sinopharm Group Corporation Information

11.3.2 Sinopharm Group Business Overview

11.3.3 Sinopharm Group Ifosfamide for Injection Product Models, Descriptions and Specifications

11.3.4 Sinopharm Group Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 Sinopharm Group Ifosfamide for Injection Sales by Product in 2024

11.3.6 Sinopharm Group Ifosfamide for Injection Sales by Application in 2024

11.3.7 Sinopharm Group Ifosfamide for Injection Sales by Geographic Area in 2024

11.3.8 Sinopharm Group Ifosfamide for Injection SWOT Analysis

11.3.9 Sinopharm Group Recent Developments

11.4 Hainan Zhuotai Pharmaceuticals

11.4.1 Hainan Zhuotai Pharmaceuticals Corporation Information

11.4.2 Hainan Zhuotai Pharmaceuticals Business Overview

11.4.3 Hainan Zhuotai Pharmaceuticals Ifosfamide for Injection Product Models, Descriptions and Specifications

11.4.4 Hainan Zhuotai Pharmaceuticals Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Hainan Zhuotai Pharmaceuticals Ifosfamide for Injection Sales by Product in 2024

11.4.6 Hainan Zhuotai Pharmaceuticals Ifosfamide for Injection Sales by Application in 2024

11.4.7 Hainan Zhuotai Pharmaceuticals Ifosfamide for Injection Sales by Geographic Area in 2024

11.4.8 Hainan Zhuotai Pharmaceuticals Ifosfamide for Injection SWOT Analysis

11.4.9 Hainan Zhuotai Pharmaceuticals Recent Developments

11.5 Nanjing Pharmaceutical Factory

11.5.1 Nanjing Pharmaceutical Factory Corporation Information

11.5.2 Nanjing Pharmaceutical Factory Business Overview

11.5.3 Nanjing Pharmaceutical Factory Ifosfamide for Injection Product Models, Descriptions and Specifications

11.5.4 Nanjing Pharmaceutical Factory Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Nanjing Pharmaceutical Factory Ifosfamide for Injection Sales by Product in 2024

11.5.6 Nanjing Pharmaceutical Factory Ifosfamide for Injection Sales by Application in 2024

11.5.7 Nanjing Pharmaceutical Factory Ifosfamide for Injection Sales by Geographic Area in 2024

11.5.8 Nanjing Pharmaceutical Factory Ifosfamide for Injection SWOT Analysis

11.5.9 Nanjing Pharmaceutical Factory Recent Developments

11.6 Qilu Pharmaceuticals

11.6.1 Qilu Pharmaceuticals Corporation Information

11.6.2 Qilu Pharmaceuticals Business Overview

11.6.3 Qilu Pharmaceuticals Ifosfamide for Injection Product Models, Descriptions and Specifications

11.6.4 Qilu Pharmaceuticals Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 Qilu Pharmaceuticals Recent Developments

11.7 Jiangsu Hengrui Medicines

11.7.1 Jiangsu Hengrui Medicines Corporation Information

11.7.2 Jiangsu Hengrui Medicines Business Overview

11.7.3 Jiangsu Hengrui Medicines Ifosfamide for Injection Product Models, Descriptions and Specifications

11.7.4 Jiangsu Hengrui Medicines Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 Jiangsu Hengrui Medicines Recent Developments

11.8 Shanxi Pude Pharmaceuticals

11.8.1 Shanxi Pude Pharmaceuticals Corporation Information

11.8.2 Shanxi Pude Pharmaceuticals Business Overview

11.8.3 Shanxi Pude Pharmaceuticals Ifosfamide for Injection Product Models, Descriptions and Specifications

11.8.4 Shanxi Pude Pharmaceuticals Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.8.5 Shanxi Pude Pharmaceuticals Recent Developments

11.9 Baxter

11.9.1 Baxter Corporation Information

11.9.2 Baxter Business Overview

11.9.3 Baxter Ifosfamide for Injection Product Models, Descriptions and Specifications

11.9.4 Baxter Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.9.5 Baxter Recent Developments

11.10 Fresenius Kabi Pharmaceuticals

11.10.1 Fresenius Kabi Pharmaceuticals Corporation Information

11.10.2 Fresenius Kabi Pharmaceuticals Business Overview

11.10.3 Fresenius Kabi Pharmaceuticals Ifosfamide for Injection Product Models, Descriptions and Specifications

11.10.4 Fresenius Kabi Pharmaceuticals Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.10.5 Fresenius Kabi Pharmaceuticals Recent Developments

11.11 Pfizer

11.11.1 Pfizer Corporation Information

11.11.2 Pfizer Business Overview

11.11.3 Pfizer Ifosfamide for Injection Product Models, Descriptions and Specifications

11.11.4 Pfizer Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.11.5 Pfizer Recent Developments

11.12 Mylan

11.12.1 Mylan Corporation Information

11.12.2 Mylan Business Overview

11.12.3 Mylan Ifosfamide for Injection Product Models, Descriptions and Specifications

11.12.4 Mylan Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.12.5 Mylan Recent Developments

11.13 Hikma Pharmaceuticals

11.13.1 Hikma Pharmaceuticals Corporation Information

11.13.2 Hikma Pharmaceuticals Business Overview

11.13.3 Hikma Pharmaceuticals Ifosfamide for Injection Product Models, Descriptions and Specifications

11.13.4 Hikma Pharmaceuticals Ifosfamide for Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.13.5 Hikma Pharmaceuticals Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 Ifosfamide for Injection Industry Chain

12.2 Ifosfamide for Injection Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 Ifosfamide for Injection Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 Ifosfamide for Injection Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Ifosfamide for Injection Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Ifosfamide for Injection Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Manufacturer

Hanhui Pharmaceuticals

Harbin Sanlian Pharmaceuticals

Sinopharm Group

Nanjing Pharmaceutical Factory

Qilu Pharmaceuticals

Baxter

Fresenius Kabi Pharmaceuticals

Pfizer Inc

Mylan NV

Hikma Pharmaceuticals

Hainan Zhuotai Pharmaceuticals

Jiangsu Hengrui Medicines

Shanxi Pude Pharmaceuticals

List of Tables

Table 1. Global Ifosfamide for Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Ifosfamide for Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Ifosfamide for Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Ifosfamide for Injection Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Ifosfamide for Injection Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Ifosfamide for Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Table 7. Global Ifosfamide for Injection Sales by Region (2020-2025) & (K Units)

Table 8. Global Ifosfamide for Injection Sales by Region (2026-2031) & (K Units)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Ifosfamide for Injection Sales by Manufacturers (2020-2025) & (K Units)

Table 11. Global Ifosfamide for Injection Sales Share by Manufacturers (2020-2025)

Table 12. Global Ifosfamide for Injection Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global Ifosfamide for Injection Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global Ifosfamide for Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ifosfamide for Injection as of 2024)

Table 16. Global Ifosfamide for Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global Ifosfamide for Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Key Manufacturers Ifosfamide for Injection Manufacturing Base and Headquarters

Table 19. Global Ifosfamide for Injection Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global Ifosfamide for Injection Sales by Type (2020-2025) & (K Units)

Table 23. Global Ifosfamide for Injection Sales by Type (2026-2031) & (K Units)

Table 24. Global Ifosfamide for Injection Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global Ifosfamide for Injection Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global Ifosfamide for Injection ASP by Type (2020-2031) & (US$/Unit)

Table 27. Technical Specifications by Key Product Type

Table 28. Global Ifosfamide for Injection Sales by Application (2020-2025) & (K Units)

Table 29. Global Ifosfamide for Injection Sales by Application (2026-2031) & (K Units)

Table 30. Ifosfamide for Injection High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global Ifosfamide for Injection Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global Ifosfamide for Injection Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global Ifosfamide for Injection ASP by Application (2020-2031) & (US$/Unit)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America Ifosfamide for Injection Growth Accelerators and Market Barriers

Table 37. North America Ifosfamide for Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America Ifosfamide for Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 39. Europe Ifosfamide for Injection Growth Accelerators and Market Barriers

Table 40. Europe Ifosfamide for Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe Ifosfamide for Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific Ifosfamide for Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific Ifosfamide for Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific Ifosfamide for Injection Growth Accelerators and Market Barriers

Table 45. Southeast Asia Ifosfamide for Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America Ifosfamide for Injection Investment Opportunities and Key Challenges

Table 47. Central and South America Ifosfamide for Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa Ifosfamide for Injection Investment Opportunities and Key Challenges

Table 49. Middle East and Africa Ifosfamide for Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Hanhui Pharmaceuticals Corporation Information

Table 51. Hanhui Pharmaceuticals Description and Major Businesses

Table 52. Hanhui Pharmaceuticals Product Models, Descriptions and Specifications

Table 53. Hanhui Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 54. Hanhui Pharmaceuticals Sales Value Proportion by Product in 2024

Table 55. Hanhui Pharmaceuticals Sales Value Proportion by Application in 2024

Table 56. Hanhui Pharmaceuticals Sales Value Proportion by Geographic Area in 2024

Table 57. Hanhui Pharmaceuticals Ifosfamide for Injection SWOT Analysis

Table 58. Hanhui Pharmaceuticals Recent Developments

Table 59. Harbin Sanlian Pharmaceuticals Corporation Information

Table 60. Harbin Sanlian Pharmaceuticals Description and Major Businesses

Table 61. Harbin Sanlian Pharmaceuticals Product Models, Descriptions and Specifications

Table 62. Harbin Sanlian Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 63. Harbin Sanlian Pharmaceuticals Sales Value Proportion by Product in 2024

Table 64. Harbin Sanlian Pharmaceuticals Sales Value Proportion by Application in 2024

Table 65. Harbin Sanlian Pharmaceuticals Sales Value Proportion by Geographic Area in 2024

Table 66. Harbin Sanlian Pharmaceuticals Ifosfamide for Injection SWOT Analysis

Table 67. Harbin Sanlian Pharmaceuticals Recent Developments

Table 68. Sinopharm Group Corporation Information

Table 69. Sinopharm Group Description and Major Businesses

Table 70. Sinopharm Group Product Models, Descriptions and Specifications

Table 71. Sinopharm Group Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 72. Sinopharm Group Sales Value Proportion by Product in 2024

Table 73. Sinopharm Group Sales Value Proportion by Application in 2024

Table 74. Sinopharm Group Sales Value Proportion by Geographic Area in 2024

Table 75. Sinopharm Group Ifosfamide for Injection SWOT Analysis

Table 76. Sinopharm Group Recent Developments

Table 77. Hainan Zhuotai Pharmaceuticals Corporation Information

Table 78. Hainan Zhuotai Pharmaceuticals Description and Major Businesses

Table 79. Hainan Zhuotai Pharmaceuticals Product Models, Descriptions and Specifications

Table 80. Hainan Zhuotai Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 81. Hainan Zhuotai Pharmaceuticals Sales Value Proportion by Product in 2024

Table 82. Hainan Zhuotai Pharmaceuticals Sales Value Proportion by Application in 2024

Table 83. Hainan Zhuotai Pharmaceuticals Sales Value Proportion by Geographic Area in 2024

Table 84. Hainan Zhuotai Pharmaceuticals Ifosfamide for Injection SWOT Analysis

Table 85. Hainan Zhuotai Pharmaceuticals Recent Developments

Table 86. Nanjing Pharmaceutical Factory Corporation Information

Table 87. Nanjing Pharmaceutical Factory Description and Major Businesses

Table 88. Nanjing Pharmaceutical Factory Product Models, Descriptions and Specifications

Table 89. Nanjing Pharmaceutical Factory Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Nanjing Pharmaceutical Factory Sales Value Proportion by Product in 2024

Table 91. Nanjing Pharmaceutical Factory Sales Value Proportion by Application in 2024

Table 92. Nanjing Pharmaceutical Factory Sales Value Proportion by Geographic Area in 2024

Table 93. Nanjing Pharmaceutical Factory Ifosfamide for Injection SWOT Analysis

Table 94. Nanjing Pharmaceutical Factory Recent Developments

Table 95. Qilu Pharmaceuticals Corporation Information

Table 96. Qilu Pharmaceuticals Description and Major Businesses

Table 97. Qilu Pharmaceuticals Product Models, Descriptions and Specifications

Table 98. Qilu Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. Qilu Pharmaceuticals Recent Developments

Table 100. Jiangsu Hengrui Medicines Corporation Information

Table 101. Jiangsu Hengrui Medicines Description and Major Businesses

Table 102. Jiangsu Hengrui Medicines Product Models, Descriptions and Specifications

Table 103. Jiangsu Hengrui Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. Jiangsu Hengrui Medicines Recent Developments

Table 105. Shanxi Pude Pharmaceuticals Corporation Information

Table 106. Shanxi Pude Pharmaceuticals Description and Major Businesses

Table 107. Shanxi Pude Pharmaceuticals Product Models, Descriptions and Specifications

Table 108. Shanxi Pude Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 109. Shanxi Pude Pharmaceuticals Recent Developments

Table 110. Baxter Corporation Information

Table 111. Baxter Description and Major Businesses

Table 112. Baxter Product Models, Descriptions and Specifications

Table 113. Baxter Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 114. Baxter Recent Developments

Table 115. Fresenius Kabi Pharmaceuticals Corporation Information

Table 116. Fresenius Kabi Pharmaceuticals Description and Major Businesses

Table 117. Fresenius Kabi Pharmaceuticals Product Models, Descriptions and Specifications

Table 118. Fresenius Kabi Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 119. Fresenius Kabi Pharmaceuticals Recent Developments

Table 120. Pfizer Corporation Information

Table 121. Pfizer Description and Major Businesses

Table 122. Pfizer Product Models, Descriptions and Specifications

Table 123. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 124. Pfizer Recent Developments

Table 125. Mylan Corporation Information

Table 126. Mylan Description and Major Businesses

Table 127. Mylan Product Models, Descriptions and Specifications

Table 128. Mylan Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 129. Mylan Recent Developments

Table 130. Hikma Pharmaceuticals Corporation Information

Table 131. Hikma Pharmaceuticals Description and Major Businesses

Table 132. Hikma Pharmaceuticals Product Models, Descriptions and Specifications

Table 133. Hikma Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 134. Hikma Pharmaceuticals Recent Developments

Table 135. Key Raw Materials Distribution

Table 136. Raw Materials Key Suppliers

Table 137. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 138. Milestones in Production Technology Evolution

Table 139. Distributors List

Table 140. Market Trends and Market Evolution

Table 141. Market Drivers and Opportunities

Table 142. Market Challenges, Risks, and Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

List of Figures

Figure 1. Ifosfamide for Injection Product Picture

Figure 2. Global Ifosfamide for Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. 3.0g Product Picture

Figure 4. 1.0g Product Picture

Figure 5. 0.5g Product Picture

Figure 6. Global Ifosfamide for Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 7. Hospital

Figure 8. Clinic

Figure 9. Other

Figure 10. Ifosfamide for Injection Report Years Considered

Figure 11. Global Ifosfamide for Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 13. Global Ifosfamide for Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 14. Global Ifosfamide for Injection Revenue Market Share by Region (2020-2031)

Figure 15. Global Ifosfamide for Injection Sales (2020-2031) & (K Units)

Figure 16. Global Ifosfamide for Injection Sales (CAGR) by Region (2020-2031) (K Units)

Figure 17. Global Ifosfamide for Injection Sales Market Share by Region (2020-2031)

Figure 18. Top 5 and Top 10 Manufacturers Ifosfamide for Injection Sales Volume Market Share in 2024

Figure 19. Global Ifosfamide for Injection Revenue Market Share Ranking (2024)

Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 21. 3.0g Revenue Market Share by Manufacturer in 2024

Figure 22. 1.0g Revenue Market Share by Manufacturer in 2024

Figure 23. 0.5g Revenue Market Share by Manufacturer in 2024

Figure 24. Global Ifosfamide for Injection Sales Market Share by Type (2020-2031)

Figure 25. Global Ifosfamide for Injection Revenue Market Share by Type (2020-2031)

Figure 26. Global Ifosfamide for Injection Sales Market Share by Application (2020-2031)

Figure 27. Global Ifosfamide for Injection Revenue Market Share by Application (2020-2031)

Figure 28. North America Ifosfamide for Injection Sales YoY (2020-2031) & (K Units)

Figure 29. North America Ifosfamide for Injection Revenue YoY (2020-2031) & (US$ Million)

Figure 30. North America Top 5 Manufacturers Ifosfamide for Injection Sales Revenue (US$ Million) in 2024

Figure 31. North America Ifosfamide for Injection Sales Volume (K Units) by Type (2020- 2031)

Figure 32. North America Ifosfamide for Injection Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 33. North America Ifosfamide for Injection Sales Volume (K Units) by Application (2020-2031)

Figure 34. North America Ifosfamide for Injection Sales Revenue (US$ Million) by Application (2020-2031)

Figure 35. US Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 36. Canada Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 37. Mexico Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 38. Europe Ifosfamide for Injection Sales YoY (2020-2031) & (K Units)

Figure 39. Europe Ifosfamide for Injection Revenue YoY (2020-2031) & (US$ Million)

Figure 40. Europe Top 5 Manufacturers Ifosfamide for Injection Sales Revenue (US$ Million) in 2024

Figure 41. Europe Ifosfamide for Injection Sales Volume (K Units) by Type (2020-2031)

Figure 42. Europe Ifosfamide for Injection Sales Revenue (US$ Million) by Type (2020-2031)

Figure 43. Europe Ifosfamide for Injection Sales Volume (K Units) by Application (2020-2031)

Figure 44. Europe Ifosfamide for Injection Sales Revenue (US$ Million) by Application (2020-2031)

Figure 45. Germany Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 46. France Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 47. U.K. Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 48. Italy Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 49. Russia Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 50. Asia-Pacific Ifosfamide for Injection Sales YoY (2020-2031) & (K Units)

Figure 51. Asia-Pacific Ifosfamide for Injection Revenue YoY (2020-2031) & (US$ Million)

Figure 52. Asia-Pacific Top 8 Manufacturers Ifosfamide for Injection Sales Revenue (US$ Million) in 2024

Figure 53. Asia-Pacific Ifosfamide for Injection Sales Volume (K Units) by Type (2020- 2031)

Figure 54. Asia-Pacific Ifosfamide for Injection Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 55. Asia-Pacific Ifosfamide for Injection Sales Volume (K Units) by Application (2020-2031)

Figure 56. Asia-Pacific Ifosfamide for Injection Sales Revenue (US$ Million) by Application (2020-2031)

Figure 57. Indonesia Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 58. Japan Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 59. South Korea Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 60. China Taiwan Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 61. India Ifosfamide for Injection Revenue (2020-2031) & (US$ Million)

Figure 62. Central and South America Ifosfamide for Injection Sales YoY (2020-2031) & (K Units)

Figure 63. Central and South America Ifosfamide for Injection Revenue YoY (2020-2031) & (US$ Million)

Figure 64. Central and South America Top 5 Manufacturers Ifosfamide for Injection Sales Revenue (US$ Million) in 2024

Figure 65. Central and South America Ifosfamide for Injection Sales Volume (K Units) by Type (2021-2031)

Figure 66. Central and South America Ifosfamide for Injection Sales Revenue (US$ Million) by Type (2020-2031)

Figure 67. Central and South America Ifosfamide for Injection Sales Volume (K Units) by Application (2020-2031)

Figure 68. Central and South America Ifosfamide for Injection Sales Revenue (US$ Million) by Application (2020-2031)

Figure 69. Brazil Ifosfamide for Injection Revenue (2020-2025) & (US$ Million)

Figure 70. Argentina Ifosfamide for Injection Revenue (2020-2025) & (US$ Million)

Figure 71. Middle East, and Africa Ifosfamide for Injection Sales YoY (2020-2031) & (K Units)

Figure 72. Middle East and Africa Ifosfamide for Injection Revenue YoY (2020-2031) & (US$ Million)

Figure 73. Middle East and Africa Top 5 Manufacturers Ifosfamide for Injection Sales Revenue (US$ Million) in 2024

Figure 74. Middle East and Africa Ifosfamide for Injection Sales Volume (K Units) by Type (2021-2031)

Figure 75. South America Ifosfamide for Injection Sales Revenue (US$ Million) by Type (2020-2031)

Figure 76. Middle East and Africa Ifosfamide for Injection Sales Volume (K Units) by Application (2020-2031)

Figure 77. Middle East and Africa Ifosfamide for Injection Sales Revenue (US$ Million) by Application (2020-2031)

Figure 78. GCC Countries Ifosfamide for Injection Revenue (2020-2025) & (US$ Million)

Figure 79. Turkey Ifosfamide for Injection Revenue (2020-2025) & (US$ Million)

Figure 80. Egypt Ifosfamide for Injection Revenue (2020-2025) & (US$ Million)

Figure 81. South Africa Ifosfamide for Injection Revenue (2020-2025) & (US$ Million)

Figure 82. Ifosfamide for Injection Industry Chain Mapping

Figure 83. Regional Ifosfamide for Injection Manufacturing Base Distribution (%)

Figure 84. Global Ifosfamide for Injection Production Market Share by Region (2020-2031)

Figure 85. Ifosfamide for Injection Production Process

Figure 86. Regional Ifosfamide for Injection Production Cost Structure

Figure 87. Channels of Distribution (Direct Vs Distribution)

Figure 88. Bottom-up and Top-down Approaches for This Report

Figure 89. Data Triangulation

Figure 90. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-26S19632

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Global Ifosfamide for Injection Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-30A19656

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Global Montelukast Sodium Tablet Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-27H17544

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Grade Omega-3 Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-10A20150

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Ifosfamide for Injection Market Outlook, In‑Depth Analysis & Forecast to 2031

Published Date: October 2025

Report Code: QYRE-Auto-30A19656

Global Ifosfamide for Injection Market Outlook, In‑Depth Analysis & Forecast to 2031

FEATURED COMPANIES

Ifosfamide for Injection Market

Report Includes:

Scope of Ifosfamide for Injection Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Ifosfamide for Injection Market report?

What are the Application segmentation covered in the Ifosfamide for Injection Market report?

What are the Type segmentation covered in the Ifosfamide for Injection Market report?

FEATURED COMPANIES

RELATED REPORTS